Compare GEO & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEO | NVAX |
|---|---|---|
| Founded | 1984 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.1B |
| IPO Year | 1994 | 1995 |
| Metric | GEO | NVAX |
|---|---|---|
| Price | $16.46 | $6.98 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 8 |
| Target Price | ★ $41.00 | $9.75 |
| AVG Volume (30 Days) | 1.8M | ★ 3.2M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 515.49 | N/A |
| EPS | 1.69 | ★ 2.07 |
| Revenue | ★ $2,531,574,000.00 | $1,064,651,000.00 |
| Revenue This Year | $7.93 | $58.91 |
| Revenue Next Year | $15.02 | N/A |
| P/E Ratio | $9.61 | ★ $3.28 |
| Revenue Growth | 4.43 | ★ 20.27 |
| 52 Week Low | $14.27 | $5.01 |
| 52 Week High | $36.46 | $11.55 |
| Indicator | GEO | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 51.89 |
| Support Level | $16.11 | $6.36 |
| Resistance Level | $16.91 | $6.98 |
| Average True Range (ATR) | 0.58 | 0.23 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 42.36 | 85.93 |
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.